-
2
-
-
85012839775
-
Amphotericin B-induced nephrotoxicity
-
10.1016/B978-0-08-046884-6.00818-6
-
Ulozas E (2010) Amphotericin B-induced nephrotoxicity. Compr Toxicol 7:347-357
-
(2010)
Compr Toxicol
, vol.7
, pp. 347-357
-
-
Ulozas, E.1
-
3
-
-
0025256091
-
Amphotericin B: 30 years of clinical experience
-
2184499 10.1093/clinids/12.2.308 1:STN:280:DyaK3c3jt1aqtg%3D%3D
-
Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12:308-329
-
(1990)
Rev Infect Dis
, vol.12
, pp. 308-329
-
-
Gallis, H.A.1
Drew, R.H.2
Pickard, W.W.3
-
4
-
-
0029014618
-
Sodium chloride treatment of amphotericin B nephrotoxicity-standard of care?
-
7747495 1:STN:280:DyaK2M3ms1egtg%3D%3D
-
Anderson CM (1995) Sodium chloride treatment of amphotericin B nephrotoxicity-standard of care? West J Med 162:313-317
-
(1995)
West J Med
, vol.162
, pp. 313-317
-
-
Anderson, C.M.1
-
5
-
-
0035173531
-
The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy
-
11705428 10.1016/S0002-9343(01)00928-7 1:CAS:528:DC%2BD3MXot1OmurY%3D
-
Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH (2001) The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111:528-534
-
(2001)
Am J Med
, vol.111
, pp. 528-534
-
-
Harbarth, S.1
Pestotnik, S.L.2
Lloyd, J.F.3
Burke, J.P.4
Samore, M.H.5
-
6
-
-
0034525028
-
Amphotericin B-induced nephrotoxicity: A review
-
11154026 1:CAS:528:DC%2BD3MXkvVOmtw%3D%3D
-
Fanos V, Cataldi L (2000) Amphotericin B-induced nephrotoxicity: a review. J Chemother 12(6):463-470
-
(2000)
J Chemother
, vol.12
, Issue.6
, pp. 463-470
-
-
Fanos, V.1
Cataldi, L.2
-
7
-
-
3543097595
-
Amphotericin B nephrotoxicity in children
-
15218415 10.1097/00043426-200407000-00004
-
Goldman RD, Koren G (2004) Amphotericin B nephrotoxicity in children. J Pediatr Hematol Oncol 26:421-426
-
(2004)
J Pediatr Hematol Oncol
, vol.26
, pp. 421-426
-
-
Goldman, R.D.1
Koren, G.2
-
8
-
-
26444551209
-
Drug-induced hypomagnesaemia: Scope and management
-
16119971 10.2165/00002018-200528090-00003 1:CAS:528:DC%2BD2MXhtFWmsbvN
-
Atsmon J, Dolev E (2005) Drug-induced hypomagnesaemia: scope and management. Drug Saf 28:763-788
-
(2005)
Drug Saf
, vol.28
, pp. 763-788
-
-
Atsmon, J.1
Dolev, E.2
-
9
-
-
0025830941
-
Effect of salt supplementation on amphotericin B nephrotoxicity
-
1942779 10.1038/ki.1991.214 1:CAS:528:DyaK3MXlt1Knur8%3D
-
Llanos A, Cieza J, Bernardo J et al (1991) Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 40:302-308
-
(1991)
Kidney Int
, vol.40
, pp. 302-308
-
-
Llanos, A.1
Cieza, J.2
Bernardo, J.3
-
10
-
-
0033966980
-
Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia
-
10669191 10.1345/aph.19127 1:CAS:528:DC%2BD3cXptVKktg%3D%3D
-
Wazny LD, Brophy DF (2000) Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia. Ann Pharmacother 34:94-97
-
(2000)
Ann Pharmacother
, vol.34
, pp. 94-97
-
-
Wazny, L.D.1
Brophy, D.F.2
-
11
-
-
0035282477
-
Mortality and costs of acute renal failure associated with amphotericin B therapy
-
11229835 10.1086/319211 1:CAS:528:DC%2BD3MXislymu70%3D
-
Bates DW, Su L, Yu DT et al (2001) Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32:686-693
-
(2001)
Clin Infect Dis
, vol.32
, pp. 686-693
-
-
Bates, D.W.1
Su, L.2
Yu, D.T.3
-
12
-
-
84867816193
-
Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
-
22950480 10.1517/14740338.2012.721775 1:CAS:528:DC%2BC38XhsFCgtrfP
-
Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidaki S (2012) Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opin Drug Saf 11:969-983
-
(2012)
Expert Opin Drug Saf
, vol.11
, pp. 969-983
-
-
Karimzadeh, I.1
Farsaei, S.2
Khalili, H.3
Dashti-Khavidaki, S.4
-
13
-
-
33846292516
-
Prevention of acute renal failure
-
17218591 10.1378/chest.06-1246 1:CAS:528:DC%2BD2sXhs1aksrg%3D
-
Venkataraman R, Kellum JA (2007) Prevention of acute renal failure. Chest 131:300-308
-
(2007)
Chest
, vol.131
, pp. 300-308
-
-
Venkataraman, R.1
Kellum, J.A.2
-
14
-
-
81355153909
-
Diuretics in acute kidney injury
-
22099509 10.1016/j.semnephrol.2011.09.007 1:CAS:528:DC%2BC3MXhsV2gsbnF
-
Nigwekar SU, Waikar SS (2011) Diuretics in acute kidney injury. Semin Nephrol 31:523-534
-
(2011)
Semin Nephrol
, vol.31
, pp. 523-534
-
-
Nigwekar, S.U.1
Waikar, S.S.2
-
15
-
-
0015291286
-
The use of mannitol to reduce the nephrotoxicity of amphotericin B
-
5009568 1:CAS:528:DyaE38XhsV2js7o%3D
-
Hellebusch AA, Salama F, Eadie E (1972) The use of mannitol to reduce the nephrotoxicity of amphotericin B. Surg Gynecol Obstet 134:241-243
-
(1972)
Surg Gynecol Obstet
, vol.134
, pp. 241-243
-
-
Hellebusch, A.A.1
Salama, F.2
Eadie, E.3
-
16
-
-
0017297419
-
Reduction of amphotericin B nephrotoxicity with mannitol
-
946511 10.1001/jama.1976.03260440047022 1:STN:280:DyaE287kslWlsQ%3D%3D
-
Rosch JM, Pazin GJ, Fireman P (1976) Reduction of amphotericin B nephrotoxicity with mannitol. JAMA 235:1995-1996
-
(1976)
JAMA
, vol.235
, pp. 1995-1996
-
-
Rosch, J.M.1
Pazin, G.J.2
Fireman, P.3
-
17
-
-
0016635716
-
Mitigation of amphotericin B nephrotoxicity by mannitol
-
1095113 10.1136/bmj.1.5957.550 1:STN:280:DyaE2M7osVOgtg%3D%3D
-
Olivero JJ, Lozano-Mendez J, Ghafary EM, Eknoyan G, Suki WN (1975) Mitigation of amphotericin B nephrotoxicity by mannitol. Br Med J 1:550-551
-
(1975)
Br Med J
, vol.1
, pp. 550-551
-
-
Olivero, J.J.1
Lozano-Mendez, J.2
Ghafary, E.M.3
Eknoyan, G.4
Suki, W.N.5
-
18
-
-
0017102142
-
Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys
-
791105 10.1128/AAC.10.3.555 1:STN:280:DyaE2s%2FktlertQ%3D%3D
-
Bullock WE, Luke RG, Nuttall CE, Bhathena D (1976) Can mannitol reduce amphotericin B nephrotoxicity? Double-blind study and description of a new vascular lesion in kidneys. Antimicrob Agents Chemother 10:555-563
-
(1976)
Antimicrob Agents Chemother
, vol.10
, pp. 555-563
-
-
Bullock, W.E.1
Luke, R.G.2
Nuttall, C.E.3
Bhathena, D.4
-
19
-
-
0017656335
-
Improvement of cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model
-
856436 10.1002/1097-0142(197704)39:4<1357: AID-CNCR2820390402>3.0. CO;2-C 1:CAS:528:DyaE2sXkslynt7c%3D
-
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357-1361
-
(1977)
Cancer
, vol.39
, pp. 1357-1361
-
-
Cvitkovic, E.1
Spaulding, J.2
Bethune, V.3
Martin, J.4
Whitmore, W.F.5
-
20
-
-
0020062969
-
Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study
-
6796269 1:STN:280:DyaL38%2FntVWrtQ%3D%3D
-
Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31-35
-
(1982)
Cancer Treat Rep
, vol.66
, pp. 31-35
-
-
Al-Sarraf, M.1
Fletcher, W.2
Oishi, N.3
Pugh, R.4
Hewlett, J.S.5
Balducci, L.6
McCracken, J.7
Padilla, F.8
-
21
-
-
0023934062
-
Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients
-
3290263 10.1136/jcp.41.5.494 1:STN:280:DyaL1c3lslGiuw%3D%3D
-
Smith SR, Galloway MJ, Reilly JT, Davies JM (1988) Amiloride prevents amphotericin B related hypokalaemia in neutropenic patients. J Clin Pathol 41:494-497
-
(1988)
J Clin Pathol
, vol.41
, pp. 494-497
-
-
Smith, S.R.1
Galloway, M.J.2
Reilly, J.T.3
Davies, J.M.4
-
22
-
-
0034916315
-
The effect of amiloride on amphotericin B-induced hypokalaemia
-
11418519 10.1093/jac/48.1.109 1:CAS:528:DC%2BD3MXlsVegtbk%3D
-
Bearden DT, Muncey LA (2001) The effect of amiloride on amphotericin B-induced hypokalaemia. J Antimicrob Chemother 48:109-111
-
(2001)
J Antimicrob Chemother
, vol.48
, pp. 109-111
-
-
Bearden, D.T.1
Muncey, L.A.2
-
23
-
-
80052529403
-
Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics
-
10.1111/j.1751-7176.2011.00511.x 1:CAS:528:DC%2BC3MXhsVWjsL3I
-
Epstein M, Calhoun DA (2011) Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich) 13:644-648
-
(2011)
J Clin Hypertens (Greenwich)
, vol.13
, pp. 644-648
-
-
Epstein, M.1
Calhoun, D.A.2
-
24
-
-
0035709414
-
Spironolactone: Is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
-
11868798 10.1007/s00228-001-0390-9 1:CAS:528:DC%2BD38Xos12isA%3D%3D
-
Ural AU, Avcu F, Cetin T, Beyan C, Kaptan K, Nazaroglu NK, Yalcin A (2002) Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? Eur J Clin Pharmacol 57:771-773
-
(2002)
Eur J Clin Pharmacol
, vol.57
, pp. 771-773
-
-
Ural, A.U.1
Avcu, F.2
Cetin, T.3
Beyan, C.4
Kaptan, K.5
Nazaroglu, N.K.6
Yalcin, A.7
-
25
-
-
78651470720
-
Injectable lipid emulsions-advancements, opportunities and challenges
-
20976577 10.1208/s12249-010-9526-5 1:CAS:528:DC%2BC3cXhs1alu7fK
-
Hippalgaonkar K, Majumdar S, Kansara V (2010) Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech 11:1526-1540
-
(2010)
AAPS PharmSciTech
, vol.11
, pp. 1526-1540
-
-
Hippalgaonkar, K.1
Majumdar, S.2
Kansara, V.3
-
26
-
-
0023743895
-
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis
-
3183418 10.1093/infdis/158.5.1065 1:STN:280:DyaL1M%2FjsFKgug%3D%3D
-
Kirsh R, Goldstein R, Tarloff J, Parris D, Hook J, Hanna N, Bugelski P, Poste G (1988) An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis 158:1065-1070
-
(1988)
J Infect Dis
, vol.158
, pp. 1065-1070
-
-
Kirsh, R.1
Goldstein, R.2
Tarloff, J.3
Parris, D.4
Hook, J.5
Hanna, N.6
Bugelski, P.7
Poste, G.8
-
27
-
-
0026452250
-
Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients
-
1490923 10.1093/jac/30.4.535 1:STN:280:DyaK3s7ks12ntQ%3D%3D
-
Moreau P, Milpied N, Fayette N, Ramée JF, Harousseau JL (1992) Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 30:535-541
-
(1992)
J Antimicrob Chemother
, vol.30
, pp. 535-541
-
-
Moreau, P.1
Milpied, N.2
Fayette, N.3
Ramée, J.F.4
Harousseau, J.L.5
-
28
-
-
0029616313
-
Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia
-
8672820 1:CAS:528:DyaK28Xks1CitA%3D%3D
-
Pascual B, Ayestaran A, Montoro JB, Oliveras J, Estibalez A, Julia A, Lopez A (1995) Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann Pharmacother 29:1197-1201
-
(1995)
Ann Pharmacother
, vol.29
, pp. 1197-1201
-
-
Pascual, B.1
Ayestaran, A.2
Montoro, J.B.3
Oliveras, J.4
Estibalez, A.5
Julia, A.6
Lopez, A.7
-
29
-
-
0027478044
-
Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients
-
8444659 10.1093/jac/31.1.161 1:STN:280:DyaK3s7os1Ggsw%3D%3D
-
Caillot D, Casasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G, Entezam F, Lopez J, Bonnin A, Guy H (1993) Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 31:161-169
-
(1993)
J Antimicrob Chemother
, vol.31
, pp. 161-169
-
-
Caillot, D.1
Casasnovas, O.2
Solary, E.3
Chavanet, P.4
Bonnotte, B.5
Reny, G.6
Entezam, F.7
Lopez, J.8
Bonnin, A.9
Guy, H.10
-
30
-
-
0032497111
-
Safety and toxicity of amphotericin B in glucose 5 % or intralipid 20 % in neutropenic patients with pneumonia or fever of unknown origin: Randomised study
-
10.1136/bmj.317.7155.379
-
Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U, Ganser A (1998) Safety and toxicity of amphotericin B in glucose 5 % or intralipid 20 % in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br Med J 317:379-384
-
(1998)
Br Med J
, vol.317
, pp. 379-384
-
-
Schöffski, P.1
Freund, M.2
Wunder, R.3
Petersen, D.4
Köhne, C.H.5
Hecker, H.6
Schubert, U.7
Ganser, A.8
-
31
-
-
0028212025
-
A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies
-
8040124 10.1093/jac/33.3.603 1:STN:280:DyaK2czhsVOjtw%3D%3D
-
Caillot D, Reny G, Solary E, Casasnovas O, Chavanet P, Bonnotte B, Perello L, Dumas M, Entezam F, Guy H (1994) A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother 33:603-613
-
(1994)
J Antimicrob Chemother
, vol.33
, pp. 603-613
-
-
Caillot, D.1
Reny, G.2
Solary, E.3
Casasnovas, O.4
Chavanet, P.5
Bonnotte, B.6
Perello, L.7
Dumas, M.8
Entezam, F.9
Guy, H.10
-
32
-
-
0033031249
-
Comparison of the toxicity of amphotericin B in 5 % dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
-
10348768 1:CAS:528:DyaK1MXjs12nsbw%3D
-
Nucci M, Loureiro M, Silveira F, Casali AR, Bouzas LF, Velasco E, Spector N, Pulcheri W (1999) Comparison of the toxicity of amphotericin B in 5 % dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 43:1445-1448
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1445-1448
-
-
Nucci, M.1
Loureiro, M.2
Silveira, F.3
Casali, A.R.4
Bouzas, L.F.5
Velasco, E.6
Spector, N.7
Pulcheri, W.8
-
33
-
-
0033059710
-
Amphotericin B in children with malignant disease: A comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion
-
10348763 1:CAS:528:DyaK1MXjs12nsLk%3D
-
Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW (1999) Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 43:1417-1423
-
(1999)
Antimicrob Agents Chemother
, vol.43
, pp. 1417-1423
-
-
Nath, C.E.1
Shaw, P.J.2
Gunning, R.3
McLachlan, A.J.4
Earl, J.W.5
-
34
-
-
0029030893
-
Amphotericin B does not mix with fat emulsion
-
7671046 1:STN:280:DyaK2MvgtV2ntg%3D%3D
-
Trissel LA (1995) Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm 52:1463-1464
-
(1995)
Am J Health Syst Pharm
, vol.52
, pp. 1463-1464
-
-
Trissel, L.A.1
-
35
-
-
0026759768
-
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis
-
10.1136/bmj.305.6859.921 1:STN:280:DyaK3s%2FptFGkug%3D%3D
-
Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman JP, D'Athis M, Portier H (1992) Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 305:921-925
-
(1992)
Br Med J
, vol.305
, pp. 921-925
-
-
Chavanet, P.Y.1
Garry, I.2
Charlier, N.3
Caillot, D.4
Kisterman, J.P.5
D'Athis, M.6
Portier, H.7
-
36
-
-
0030821449
-
Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate-fat emulsion in HIV-infected patients with oral candidosis
-
11864156 10.1111/j.1469-0691.1997.tb00282.x 1:CAS:528:DyaK2sXmtVGht74%3D
-
Chavanet P, Clement C, Duong M, Buisson M, D'Athis P, Dumas M, Bonnin A, Portier H (1997) Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate-fat emulsion in HIV-infected patients with oral candidosis. Clin Microbiol Infect 3:455-461
-
(1997)
Clin Microbiol Infect
, vol.3
, pp. 455-461
-
-
Chavanet, P.1
Clement, C.2
Duong, M.3
Buisson, M.4
D'Athis, P.5
Dumas, M.6
Bonnin, A.7
Portier, H.8
-
37
-
-
19244362836
-
Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis
-
8879780 10.1093/clinids/23.3.556 1:CAS:528:DyaK28XlvVGgtbc%3D
-
Joly V, Aubry P, Ndayiragide A, Carrière I, Kawa E, Mlika-Cabanne N, Aboulker JP, Coulaud JP, Larouze B, Yeni P (1996) Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 23:556-562
-
(1996)
Clin Infect Dis
, vol.23
, pp. 556-562
-
-
Joly, V.1
Aubry, P.2
Ndayiragide, A.3
Carrière, I.4
Kawa, E.5
Mlika-Cabanne, N.6
Aboulker, J.P.7
Coulaud, J.P.8
Larouze, B.9
Yeni, P.10
-
38
-
-
9344255433
-
Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: Results of a prospective, randomized, controlled study in critically ill patients
-
8706484 10.1097/00003246-199608000-00007 1:STN:280:DyaK28zit1yksw%3D%3D
-
Sorkine P, Nagar H, Weinbroum A, Setton A, Israitel E, Scarlatt A, Silbiger A, Rudick V, Kluger Y, Halpern P (1996) Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med 24:1311-1315
-
(1996)
Crit Care Med
, vol.24
, pp. 1311-1315
-
-
Sorkine, P.1
Nagar, H.2
Weinbroum, A.3
Setton, A.4
Israitel, E.5
Scarlatt, A.6
Silbiger, A.7
Rudick, V.8
Kluger, Y.9
Halpern, P.10
-
39
-
-
0032811743
-
A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients
-
10452470 10.1097/00005373-199908000-00020 1:CAS:528:DyaK1MXlslKis78%3D
-
Barquist E, Fein E, Shadick D, Johnson J, Clark J, Shatz D (1999) A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J Trauma 47:336-340
-
(1999)
J Trauma
, vol.47
, pp. 336-340
-
-
Barquist, E.1
Fein, E.2
Shadick, D.3
Johnson, J.4
Clark, J.5
Shatz, D.6
-
40
-
-
0028641193
-
Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar
-
7886778 10.1016/0035-9203(94)90236-4 1:STN:280:DyaK2M7ptlSnuw%3D%3D
-
Thakur CP (1994) Comparison of glucose versus fat emulsion in the preparation of amphotericin B for use in kala-azar. Trans R Soc Trop Med Hyg 88:698-699
-
(1994)
Trans R Soc Trop Med Hyg
, vol.88
, pp. 698-699
-
-
Thakur, C.P.1
-
41
-
-
50049110427
-
Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar
-
18664241 10.1111/j.1365-3156.2008.02128.x 1:CAS:528:DC%2BD1cXht1Shtr3I
-
Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M (2008) Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop Med Int Health 13:1208-1212
-
(2008)
Trop Med Int Health
, vol.13
, pp. 1208-1212
-
-
Sundar, S.1
Chakravarty, J.2
Agarwal, D.3
Shah, A.4
Agrawal, N.5
Rai, M.6
-
42
-
-
66149103635
-
Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis
-
19407109 1:CAS:528:DC%2BD1MXmt1Kjsr8%3D
-
Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J (2009) Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am J Trop Med Hyg 80:700-703
-
(2009)
Am J Trop Med Hyg
, vol.80
, pp. 700-703
-
-
Sundar, S.1
Singh, A.2
Agarwal, D.3
Rai, M.4
Agrawal, N.5
Chakravarty, J.6
-
43
-
-
0030812502
-
Reduction in the nephrotoxicity of amphotericin B when administered in 20 % intralipid
-
22514488 1:STN:280:DC%2BC38rmtFyltA%3D%3D
-
Salama S, Rotstein C (1997) Reduction in the nephrotoxicity of amphotericin B when administered in 20 % intralipid. Can J Infect Dis 8:157-160
-
(1997)
Can J Infect Dis
, vol.8
, pp. 157-160
-
-
Salama, S.1
Rotstein, C.2
-
44
-
-
0028908692
-
Amphotericin B toxicity reduced by administration in fat emulsion
-
7655134 1:STN:280:DyaK2MzotlOrug%3D%3D
-
Anderson RP, Clark DA (1995) Amphotericin B toxicity reduced by administration in fat emulsion. Ann Pharmacother 29:496-500
-
(1995)
Ann Pharmacother
, vol.29
, pp. 496-500
-
-
Anderson, R.P.1
Clark, D.A.2
-
45
-
-
84861525317
-
Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis
-
22491505 10.1093/cid/cis290 1:CAS:528:DC%2BC38XnvVOhtLY%3D
-
Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R (2012) Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis 54:1774-1777
-
(2012)
Clin Infect Dis
, vol.54
, pp. 1774-1777
-
-
Mistro, S.1
Maciel Ide, M.2
De Menezes, R.G.3
Maia, Z.P.4
Schooley, R.T.5
Badaró, R.6
-
46
-
-
0029932155
-
Amphotericin B is incompatible with lipid emulsions
-
8833570 1:STN:280:DyaK28vjtVCntw%3D%3D
-
Ericsson O, Hallmen AC, Wikstrom I (1996) Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother 30:298
-
(1996)
Ann Pharmacother
, vol.30
, pp. 298
-
-
Ericsson, O.1
Hallmen, A.C.2
Wikstrom, I.3
-
47
-
-
0030007112
-
Amphotericin B formulated in a lipid emulsion
-
8729899 1:CAS:528:DyaK28XislKgsrg%3D
-
Cleary JD (1996) Amphotericin B formulated in a lipid emulsion. Ann Pharmacother 30:409-412
-
(1996)
Ann Pharmacother
, vol.30
, pp. 409-412
-
-
Cleary, J.D.1
-
48
-
-
0030979790
-
Precipitation of amphotericin B from i.v. fat emulsion
-
9194992 1:STN:280:DyaK2szjvVCgsA%3D%3D
-
Heide PE (1997) Precipitation of amphotericin B from i.v. fat emulsion. Am J Health Syst Pharm 54:1449
-
(1997)
Am J Health Syst Pharm
, vol.54
, pp. 1449
-
-
Heide, P.E.1
-
49
-
-
84879082011
-
-
National Library of Medicine, National Institutes of Health Accessed 4 May 2012
-
National Library of Medicine, National Institutes of Health. Intralipid (soybean oil) emulsion. Available at: http://dailymed.nlm.nih.gov/dailymed/ drugInfo.cfm?id = 6275. Accessed 4 May 2012
-
Intralipid (Soybean Oil) Emulsion
-
-
-
50
-
-
35348926847
-
Amphotericin B and coccidioidomycosis
-
17513463 10.1196/annals.1406.019 1:CAS:528:DC%2BD2sXhtlWjsr7L
-
Johnson RH, Einstein HE (2007) Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci 1111:434-441
-
(2007)
Ann N y Acad Sci
, vol.1111
, pp. 434-441
-
-
Johnson, R.H.1
Einstein, H.E.2
-
51
-
-
0021922696
-
In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester
-
3994345 10.1128/AAC.27.3.302 1:CAS:528:DyaL2MXhslyktbw%3D
-
Kobayashi GS, Little JR, Medoff G (1985) In vitro and in vivo comparisons of amphotericin B and N-D-ornithyl amphotericin B methyl ester. Antimicrob Agents Chemother 27:302-305
-
(1985)
Antimicrob Agents Chemother
, vol.27
, pp. 302-305
-
-
Kobayashi, G.S.1
Little, J.R.2
Medoff, G.3
-
52
-
-
0002056886
-
Preparationa nd use of liposomes as models of biological membranes
-
D. KornE (eds) 1 Plenum Press New York 10.1007/978-1-4615-7422-4-1
-
BanghamA D, Hill MW, Miller NGA (1974) Preparationa nd use of liposomes as models of biological membranes. In: KornE D (ed) Methods in membrane biology, vol 1. Plenum Press, New York, pp 1-68
-
(1974)
Methods in Membrane Biology
, pp. 1-68
-
-
Banghama, D.1
Hill, M.W.2
Miller, N.G.A.3
-
53
-
-
7344264567
-
Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
-
9709879 10.1086/514672 1:CAS:528:DyaK1cXlsVOrsbs%3D
-
White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296-302
-
(1998)
Clin Infect Dis
, vol.27
, pp. 296-302
-
-
White, M.H.1
Bowden, R.A.2
Sandler, E.S.3
Graham, M.L.4
Noskin, G.A.5
Wingard, J.R.6
Goldman, M.7
Van Burik, J.A.8
McCabe, A.9
Lin, J.S.10
Gurwith, M.11
Miller, C.B.12
-
54
-
-
0030984333
-
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
-
9145737 1:CAS:528:DyaK2sXisFWrtbY%3D
-
White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA (1997) Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24:635-642
-
(1997)
Clin Infect Dis
, vol.24
, pp. 635-642
-
-
White, M.H.1
Anaissie, E.J.2
Kusne, S.3
Wingard, J.R.4
Hiemenz, J.W.5
Cantor, A.6
Gurwith, M.7
Du Mond, C.8
Mamelok, R.D.9
Bowden, R.A.10
-
55
-
-
0033046042
-
Lipid-based amphotericin B for the treatment of fungal infections
-
10221369 10.1592/phco.19.4.306.30934 1:CAS:528:DyaK1MXitVSnsLY%3D
-
Slain D (1999) Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 19:306-323
-
(1999)
Pharmacotherapy
, vol.19
, pp. 306-323
-
-
Slain, D.1
-
56
-
-
0021345457
-
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
-
6696909 10.1016/0005-2736(84)90135-4 1:CAS:528:DyaL2cXhsVCqs7o%3D
-
Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL (1984) Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 770:230-234
-
(1984)
Biochim Biophys Acta
, vol.770
, pp. 230-234
-
-
Mehta, R.1
Lopez-Berestein, G.2
Hopfer, R.3
Mills, K.4
Juliano, R.L.5
-
57
-
-
0026043820
-
Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
-
1778892 10.1093/jac/28.suppl-B.49 1:CAS:528:DyaK38Xjtl2rtA%3D%3D
-
Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother 28[Suppl B]:49-61
-
(1991)
J Antimicrob Chemother
, vol.28
, Issue.SUPPL. B
, pp. 49-61
-
-
Proffitt, R.T.1
Satorius, A.2
Chiang, S.M.3
Sullivan, L.4
Adler-Moore, J.P.5
-
58
-
-
0028266748
-
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits
-
8031034 10.1128/AAC.38.4.713 1:CAS:528:DyaK2cXivVSjurc%3D
-
Lee JW, Amantea MA, Francis PA, Navarro EE, Bacher J, Pizzo PA, Walsh TJ (1994) Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother 38:713-718
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 713-718
-
-
Lee, J.W.1
Amantea, M.A.2
Francis, P.A.3
Navarro, E.E.4
Bacher, J.5
Pizzo, P.A.6
Walsh, T.J.7
-
59
-
-
0028084861
-
Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B
-
8192447 10.1128/AAC.38.2.223 1:CAS:528:DyaK2cXhvVantrk%3D
-
Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G (1994) Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 38:223-227
-
(1994)
Antimicrob Agents Chemother
, vol.38
, pp. 223-227
-
-
Wasan, K.M.1
Rosenblum, M.G.2
Cheung, L.3
Lopez-Berestein, G.4
-
60
-
-
0026694824
-
Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity
-
1504072 10.1016/0005-2736(92)90414-H 1:CAS:528:DyaK38XlsFOms74%3D
-
Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, Janoff AS (1992) Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1107:271-282
-
(1992)
Biochim Biophys Acta
, vol.1107
, pp. 271-282
-
-
Perkins, W.R.1
Minchey, S.R.2
Boni, L.T.3
Swenson, C.E.4
Popescu, M.C.5
Pasternack, R.F.6
Janoff, A.S.7
-
61
-
-
9844239388
-
A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients
-
9332329 10.1046/j.1365-2141.1997.2473063.x 1:CAS:528:DyaK2sXmt1KrtLY%3D
-
Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711-718
-
(1997)
Br J Haematol
, vol.98
, pp. 711-718
-
-
Prentice, H.G.1
Hann, I.M.2
Herbrecht, R.3
Aoun, M.4
Kvaloy, S.5
Catovsky, D.6
Pinkerton, C.R.7
Schey, S.A.8
Jacobs, F.9
Oakhill, A.10
Stevens, R.F.11
Darbyshire, P.J.12
Gibson, B.E.13
-
62
-
-
7844233666
-
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
-
9792309 10.1046/j.1365-2141.1998.00944.x 1:CAS:528:DyaK1cXnt1aktLc%3D
-
Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, Verbrugh HA, de Marie S (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205-212
-
(1998)
Br J Haematol
, vol.103
, pp. 205-212
-
-
Leenders, A.C.1
Daenen, S.2
Jansen, R.L.3
Hop, W.C.4
Lowenberg, B.5
Wijermans, P.W.6
Cornelissen, J.7
Herbrecht, R.8
Van Der Lelie, H.9
Hoogsteden, H.C.10
Verbrugh, H.A.11
De Marie, S.12
-
63
-
-
0033545538
-
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
-
10072411 10.1056/NEJM199903113401004 1:CAS:528:DyaK1MXhvFOqu7k%3D
-
Walsh TJ, Finberg RW, Arndt C et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764-771
-
(1999)
N Engl J Med
, vol.340
, pp. 764-771
-
-
Walsh, T.J.1
Finberg, R.W.2
Arndt, C.3
-
64
-
-
0037118677
-
Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS
-
U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group 12118965 10.7326/0003-4819-137-2-200207160-00008 1:CAS:528: DC%2BD38Xmt1aitrc%3D
-
Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE, U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group (2002) Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 137:105-109
-
(2002)
Ann Intern Med
, vol.137
, pp. 105-109
-
-
Johnson, P.C.1
Wheat, L.J.2
Cloud, G.A.3
Goldman, M.4
Lancaster, D.5
Bamberger, D.M.6
Powderly, W.G.7
Hafner, R.8
Kauffman, C.A.9
Dismukes, W.E.10
-
65
-
-
9044250097
-
Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
-
8838189 10.1093/clinids/22.2.315 1:CAS:528:DyaK28Xhs1Ojs7o%3D
-
Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC Jr, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS (1996) Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22:315-321
-
(1996)
Clin Infect Dis
, vol.22
, pp. 315-321
-
-
Sharkey, P.K.1
Graybill, J.R.2
Johnson, E.S.3
Hausrath, S.G.4
Pollard, R.B.5
Kolokathis, A.6
Mildvan, D.7
Fan-Havard, P.8
Eng, R.H.9
Patterson, T.F.10
Pottage, Jr.J.C.11
Simberkoff, M.S.12
Wolf, J.13
Meyer, R.D.14
Gupta, R.15
Lee, L.W.16
Gordon, D.S.17
-
66
-
-
0025877789
-
Amphotericin B lipid complex therapy of experimental fungal infections in mice
-
2069367 10.1128/AAC.35.4.615 1:CAS:528:DyaK3MXhvF2itrY%3D
-
Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP (1991) Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35:615-621
-
(1991)
Antimicrob Agents Chemother
, vol.35
, pp. 615-621
-
-
Clark, J.M.1
Whitney, R.R.2
Olsen, S.J.3
George, R.J.4
Swerdel, M.R.5
Kunselman, L.6
Bonner, D.P.7
-
67
-
-
0027250827
-
Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS
-
8363759 10.1097/00002030-199306000-00011 1:STN:280:DyaK3szntFOisw%3D%3D
-
Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, Atouguia J, Champalimaud JL, Harris JR (1993) Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7:829-835
-
(1993)
AIDS
, vol.7
, pp. 829-835
-
-
Coker, R.J.1
Viviani, M.2
Gazzard, B.G.3
Du Pont, B.4
Pohle, H.D.5
Murphy, S.M.6
Atouguia, J.7
Champalimaud, J.L.8
Harris, J.R.9
-
68
-
-
1942436895
-
Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial
-
15059069 10.1111/j.1600-0609.2004.00239.x
-
Subirà M, Martino R, Gómez L, Martí JM, Estany C, Sierra J (2004) Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol 72:342-347
-
(2004)
Eur J Haematol
, vol.72
, pp. 342-347
-
-
Subirà, M.1
Martino, R.2
Gómez, L.3
Martí, J.M.4
Estany, C.5
Sierra, J.6
-
69
-
-
18044389505
-
Experience with community-based amphotericin B infusion therapy
-
15899731 10.1592/phco.25.5.690.63591 1:CAS:528:DC%2BD2MXks1aisLs%3D
-
Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA (2005) Experience with community-based amphotericin B infusion therapy. Pharmacotherapy 25:690-697
-
(2005)
Pharmacotherapy
, vol.25
, pp. 690-697
-
-
Malani, P.N.1
Depestel, D.D.2
Riddell, J.3
Bickley, S.4
Klein, L.R.5
Kauffman, C.A.6
-
70
-
-
33747443131
-
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries
-
Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators 16838223 10.1086/505969
-
Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators (2006) Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 43:e29-e38
-
(2006)
Clin Infect Dis
, vol.43
-
-
Ullmann, A.J.1
Sanz, M.A.2
Tramarin, A.3
Barnes, R.A.4
Wu, W.5
Gerlach, B.A.6
Krobot, K.J.7
Gerth, W.C.8
-
71
-
-
0031710982
-
A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology
-
9792308 10.1046/j.1365-2141.1998.00934.x 1:CAS:528:DyaK1cXnt1aksLk%3D
-
Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R (1998) A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 103:198-204
-
(1998)
Br J Haematol
, vol.103
, pp. 198-204
-
-
Clark, A.D.1
McKendrick, S.2
Tansey, P.J.3
Franklin, I.M.4
Chopra, R.5
-
72
-
-
0034456963
-
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group
-
L Amph/ABLC Collaborative Study Group 11073745 10.1086/317451 1:CAS:528:DC%2BD3MXhsVKhtg%3D%3D
-
Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, L Amph/ABLC Collaborative Study Group (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 31:1155-1163
-
(2000)
Clin Infect Dis
, vol.31
, pp. 1155-1163
-
-
Wingard, J.R.1
White, M.H.2
Anaissie, E.3
Raffalli, J.4
Goodman, J.5
Arrieta, A.6
-
73
-
-
0035049295
-
Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia
-
11426524 10.3109/10428190109097650 1:CAS:528:DC%2BD3MXjtVCjtbo%3D
-
Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E (2001) Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 40:511-520
-
(2001)
Leuk Lymphoma
, vol.40
, pp. 511-520
-
-
Fleming, R.V.1
Kantarjian, H.M.2
Husni, R.3
Rolston, K.4
Lim, J.5
Raad, I.6
Pierce, S.7
Cortes, J.8
Estey, E.9
-
74
-
-
0034861678
-
A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations
-
11560200 10.1592/phco.21.13.1107.34613 1:CAS:528:DC%2BD3MXnt1Wgsbc%3D
-
Cannon JP, Garey KW, Danziger LH (2001) A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 21:1107-1114
-
(2001)
Pharmacotherapy
, vol.21
, pp. 1107-1114
-
-
Cannon, J.P.1
Garey, K.W.2
Danziger, L.H.3
-
75
-
-
9144238092
-
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy
-
14745876 10.1002/cncr.11936 1:CAS:528:DC%2BD2cXhs1Wrtrw%3D
-
Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E (2004) Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100:581-589
-
(2004)
Cancer
, vol.100
, pp. 581-589
-
-
Mattiuzzi, G.N.1
Kantarjian, H.2
Faderl, S.3
Lim, J.4
Kontoyiannis, D.5
Thomas, D.6
Wierda, W.7
Raad, I.8
Garcia-Manero, G.9
Zhou, X.10
Ferrajoli, A.11
Bekele, N.12
Estey, E.13
-
76
-
-
41149148599
-
Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy
-
18224662 10.1002/cncr.23311 1:CAS:528:DC%2BD1cXksFKju7g%3D
-
Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C, Kontoyiannis DP, Raad II (2008) Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 112:1282-1287
-
(2008)
Cancer
, vol.112
, pp. 1282-1287
-
-
Hachem, R.Y.1
Boktour, M.R.2
Hanna, H.A.3
Husni, R.N.4
Torres, H.A.5
Afif, C.6
Kontoyiannis, D.P.7
Raad, I.I.8
-
77
-
-
0035665846
-
Can we decrease amphotericin nephrotoxicity?
-
11805538 10.1097/00075198-200112000-00002 1:STN:280: DC%2BD38%2Fotl2iug%3D%3D
-
Costa S, Nucci M (2001) Can we decrease amphotericin nephrotoxicity? Curr Opin Crit Care 7:379-383
-
(2001)
Curr Opin Crit Care
, vol.7
, pp. 379-383
-
-
Costa, S.1
Nucci, M.2
-
78
-
-
0034565160
-
Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia
-
Johansen HK, Gotzsche PC (2000) Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2000(3):CD000969
-
(2000)
Cochrane Database Syst Rev
, vol.2000
, Issue.3
-
-
Johansen, H.K.1
Gotzsche, P.C.2
-
79
-
-
2542444843
-
Amphotericin B for the treatment of systemic fungal infections: Meta-analysis of conventional versus lipid formulations
-
42nd ICAAC, San Diego, CA, Abstract - 888
-
Macauly SS, Martin JE, Zarnke KB (2002) Amphotericin B for the treatment of systemic fungal infections: meta-analysis of conventional versus lipid formulations. In: Interscience Conf on Antimicrobial Agents and Chemotherapy. 42nd ICAAC, San Diego, CA, Abstract - 888
-
(2002)
Interscience Conf on Antimicrobial Agents and Chemotherapy
-
-
Macauly, S.S.1
Martin, J.E.2
Zarnke, K.B.3
-
80
-
-
0038282815
-
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
-
Amphotericin B Systematic Review Study Group 12867214 10.1016/S0149-2918(03)80125-X 1:CAS:528:DC%2BD3sXlsFCmsbk%3D
-
Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EG, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C, Amphotericin B Systematic Review Study Group (2003) A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 25:1295-1320
-
(2003)
Clin Ther
, vol.25
, pp. 1295-1320
-
-
Barrett, J.P.1
Vardulaki, K.A.2
Conlon, C.3
Cooke, J.4
Daza-Ramirez, P.5
Evans, E.G.6
Hawkey, P.M.7
Herbrecht, R.8
Marks, D.I.9
Moraleda, J.M.10
Park, G.R.11
Senn, S.J.12
Viscoli, C.13
-
81
-
-
1942438527
-
Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): A review of the literature
-
15119986 10.1185/030079904125003179 1:CAS:528:DC%2BD2cXksVSis7c%3D
-
Martino R (2004) Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 20:485-504
-
(2004)
Curr Med Res Opin
, vol.20
, pp. 485-504
-
-
Martino, R.1
-
82
-
-
62149098304
-
Liposomal amphotericin B: A review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections
-
19275278 10.2165/00003495-200969030-00010 1:CAS:528:DC%2BD1MXls1yls7w%3D
-
Moen MD, Lyseng-Williamson KA, Scott LJ (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69:361-392
-
(2009)
Drugs
, vol.69
, pp. 361-392
-
-
Moen, M.D.1
Lyseng-Williamson, K.A.2
Scott, L.J.3
-
83
-
-
77954751954
-
Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: A review and meta-analysis
-
20616663 10.1097/MD.0b013e3181e9441b 1:CAS:528:DC%2BC3cXosFGis7k%3D
-
Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad II (2010) Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine 89:236-244
-
(2010)
Medicine
, vol.89
, pp. 236-244
-
-
Safdar, A.1
Ma, J.2
Saliba, F.3
Dupont, B.4
Wingard, J.R.5
Hachem, R.Y.6
Mattiuzzi, G.N.7
Chandrasekar, P.H.8
Kontoyiannis, D.P.9
Rolston, K.V.10
Walsh, T.J.11
Champlin, R.E.12
Raad, I.I.13
-
84
-
-
0031686559
-
Lipid formulations of amphotericin B: Clinical efficacy and toxicities
-
9770163 10.1086/514704 1:CAS:528:DyaK1cXmt1Gkur8%3D
-
Wong-Beringer A, Jacobs RA, Guglielmo BJ (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603-618
-
(1998)
Clin Infect Dis
, vol.27
, pp. 603-618
-
-
Wong-Beringer, A.1
Jacobs, R.A.2
Guglielmo, B.J.3
-
85
-
-
0033852991
-
Pulmonary extraction and accumulation of lipid formulations of amphotericin B
-
10921589 10.1097/00003246-200007000-00056 1:CAS:528:DC%2BD3MXntFKhu7Y%3D
-
Matot I, Pizov R (2000) Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit Care Med 28:2528-2532
-
(2000)
Crit Care Med
, vol.28
, pp. 2528-2532
-
-
Matot, I.1
Pizov, R.2
-
87
-
-
0008917225
-
Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients
-
Toronto, CA, Abstract - 506
-
Greenberg RN, Cagnoni PJ, Prendergast MM, Tong KB (2000) Pharmacoeconomics of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of persistently febrile neutropenic patients. In: Interscience Conf on Antimicrobial Agents and Chemotherapy. 40th ICAAC, Toronto, CA, Abstract - 506
-
(2000)
Interscience Conf on Antimicrobial Agents and Chemotherapy. 40th ICAAC
-
-
Greenberg, R.N.1
Cagnoni, P.J.2
Prendergast, M.M.3
Tong, K.B.4
-
88
-
-
0019217687
-
Adenosine as a possible mediator of metabolic control of glomerular filtration rate
-
7399032 10.1016/0020-711X(80)90082-8 1:CAS:528:DyaL3cXmtVWqsL8%3D
-
Osswald H, Nabakowski G, Hermes H (1980) Adenosine as a possible mediator of metabolic control of glomerular filtration rate. Int J Biochem 12:263-267
-
(1980)
Int J Biochem
, vol.12
, pp. 263-267
-
-
Osswald, H.1
Nabakowski, G.2
Hermes, H.3
-
89
-
-
0020700998
-
Effect of aminophylline on amphotericin B nephrotoxicity in the dog
-
6298404 1:CAS:528:DyaL3sXhsFCqtrY%3D
-
Gerkens JF, Heidemann HT, Jackson EK, Branch RA (1983) Effect of aminophylline on amphotericin B nephrotoxicity in the dog. J Pharmacol Exp Ther 224:609-613
-
(1983)
J Pharmacol Exp Ther
, vol.224
, pp. 609-613
-
-
Gerkens, J.F.1
Heidemann, H.T.2
Jackson, E.K.3
Branch, R.A.4
-
90
-
-
0020503451
-
Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat
-
6646242 10.1007/BF00497021 1:STN:280:DyaL2c%2FmvVahsw%3D%3D
-
Heidemann HT, Gerkens JF, Jackson EK, Branch RA (1983) Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmiedebergs Arch Pharmacol 324:148-152
-
(1983)
Naunyn Schmiedebergs Arch Pharmacol
, vol.324
, pp. 148-152
-
-
Heidemann, H.T.1
Gerkens, J.F.2
Jackson, E.K.3
Branch, R.A.4
-
91
-
-
0025248525
-
Effect of an adenosine receptor antagonist on acute amphotericin B nephrotoxicity
-
2340862 10.1016/0014-2999(90)90107-H 1:CAS:528:DyaK3cXktVSiu7Y%3D
-
Kuan CJ, Branch RA, Jackson EK (1990) Effect of an adenosine receptor antagonist on acute amphotericin B nephrotoxicity. Eur J Pharmacol 178:285-291
-
(1990)
Eur J Pharmacol
, vol.178
, pp. 285-291
-
-
Kuan, C.J.1
Branch, R.A.2
Jackson, E.K.3
-
92
-
-
0025870801
-
Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058
-
1675291 1:CAS:528:DyaK3MXksVWgurs%3D
-
Brooks DP, Mitchell MP, Short BG, Ruffolo RR Jr, Nichols AJ (1991) Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058. J Pharmacol Exp Ther 257:1243-1247
-
(1991)
J Pharmacol Exp Ther
, vol.257
, pp. 1243-1247
-
-
Brooks, D.P.1
Mitchell, M.P.2
Short, B.G.3
Ruffolo, Jr.R.R.4
Nichols, A.J.5
-
93
-
-
0026500607
-
Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog
-
1346161 1:CAS:528:DyaK38Xns1Srtw%3D%3D
-
Nichols AJ, Koster PF, Brooks DP, Ruffolo RRJR (1992) Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Ther 260:269-274
-
(1992)
J Pharmacol Exp Ther
, vol.260
, pp. 269-274
-
-
Nichols, A.J.1
Koster, P.F.2
Brooks, D.P.3
Ruffolo, R.4
-
94
-
-
0024338726
-
Nifedipine and amphotericin B nephrotoxicity in the rat
-
2739868 10.1159/000185657 1:CAS:528:DyaL1MXit1Gjur4%3D
-
Soupart A, Decaux G (1989) Nifedipine and amphotericin B nephrotoxicity in the rat. Nephron 52:278-280
-
(1989)
Nephron
, vol.52
, pp. 278-280
-
-
Soupart, A.1
Decaux, G.2
-
95
-
-
0026648044
-
Direct amphotericin B-mediated tubular toxicity: Assessments of selected cytoprotective agents
-
1501413 10.1038/ki.1992.229 1:CAS:528:DyaK38XltVelt7Y%3D
-
Zager RA, Bredl CR, Schimpf BA (1992) Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents. Kidney Int 41:1588-1594
-
(1992)
Kidney Int
, vol.41
, pp. 1588-1594
-
-
Zager, R.A.1
Bredl, C.R.2
Schimpf, B.A.3
-
96
-
-
0026195956
-
Chronic amphotericin B nephrotoxicity in the rat: Protective effect of calcium channel blockade
-
1:CAS:528:DyaK38XnsFOntg%3D%3D
-
Tolins JP, Raij L (1991) Chronic amphotericin B nephrotoxicity in the rat: protective effect of calcium channel blockade. Am Soc Nephrol 2:98-102
-
(1991)
Am Soc Nephrol
, vol.2
, pp. 98-102
-
-
Tolins, J.P.1
Raij, L.2
-
97
-
-
0035111992
-
Apoptosis contributes to amphotericin B-induced nephrotoxicity
-
11181342 10.1128/AAC.45.3.679-685.2001 1:CAS:528:DC%2BD3MXhsFWgt7s%3D
-
Varlam DE, Siddiq MM, Parton LA, Rüssmann H (2001) Apoptosis contributes to amphotericin B-induced nephrotoxicity. Antimicrob Agents Chemother 45:679-685
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 679-685
-
-
Varlam, D.E.1
Siddiq, M.M.2
Parton, L.A.3
Rüssmann, H.4
-
98
-
-
0030720871
-
Cisplatin-induced renal toxicity: Possible reversal by N-acetylcysteine treatment
-
9335396 1:CAS:528:DyaK1cXhtVWqsbY%3D
-
Sheikh-Hamad D, Timmins K, Jalali Z (1997) Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 8:1640-1644
-
(1997)
J Am Soc Nephrol
, vol.8
, pp. 1640-1644
-
-
Sheikh-Hamad, D.1
Timmins, K.2
Jalali, Z.3
-
99
-
-
0032950473
-
N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats
-
10328471 10.1093/ndt/14.4.923 1:CAS:528:DyaK1MXislOgsbo%3D
-
Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A (1999) N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol Dial Transplant 14:923-929
-
(1999)
Nephrol Dial Transplant
, vol.14
, pp. 923-929
-
-
Tariq, M.1
Morais, C.2
Sobki, S.3
Al Sulaiman, M.4
Al Khader, A.5
-
100
-
-
0035854556
-
Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats
-
11470263 10.1016/S0014-2999(01)01130-X 1:CAS:528:DC%2BD3MXltlOht7o%3D
-
Mazzon E, Britti D, De Sarro A, Caputi AP, Cuzzocrea S (2001) Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 424:75-83
-
(2001)
Eur J Pharmacol
, vol.424
, pp. 75-83
-
-
Mazzon, E.1
Britti, D.2
De Sarro, A.3
Caputi, A.P.4
Cuzzocrea, S.5
-
101
-
-
0034691822
-
Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine
-
10900277 10.1056/NEJM200007203430304 1:CAS:528:DC%2BD3cXlsF2jsrs%3D
-
Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343:180-184
-
(2000)
N Engl J Med
, vol.343
, pp. 180-184
-
-
Tepel, M.1
Van Der Giet, M.2
Schwarzfeld, C.3
Laufer, U.4
Liermann, D.5
Zidek, W.6
-
102
-
-
12444326166
-
N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats
-
10.1159/000081799
-
Feldman L, Efrati S, Dishy V, Katchko L, Berman S, Averbukh M, Aladjem M, Averbukh Z, Weissgarten J (2005) N-acetylcysteine ameliorates amphotericin-induced nephropathy in rats. Nephron Physiol 99:23-27
-
(2005)
Nephron Physiol
, vol.99
, pp. 23-27
-
-
Feldman, L.1
Efrati, S.2
Dishy, V.3
Katchko, L.4
Berman, S.5
Averbukh, M.6
Aladjem, M.7
Averbukh, Z.8
Weissgarten, J.9
-
103
-
-
67649991195
-
Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine
-
19414577 10.1128/AAC.00001-09 1:CAS:528:DC%2BD1MXotlajsL4%3D
-
Odabasi Z, Karaalp A, Cermik H, Mohr J, Tigen ET, Koc M, Korten V (2009) Reduction of amphotericin B-induced renal tubular apoptosis by N-acetylcysteine. Antimicrob Agents Chemother 53:3100-3102
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 3100-3102
-
-
Odabasi, Z.1
Karaalp, A.2
Cermik, H.3
Mohr, J.4
Tigen, E.T.5
Koc, M.6
Korten, V.7
|